摘要
目的:探讨脑梗死急性期应用阿司匹林联合依替巴肽对治疗预后的影响。方法:收集2021年3月至2022年3月收治的脑梗死急性期患者60例,用随机数字表法分为对照组和观察组各30例。对照组口服阿司匹林100 mg/次,1次/d,连续2周。观察组在此基础上加用依替巴肽首剂135μg/kg,静脉推注,之后按照0.75μg·kg^(-1)·min^(-1)微量泵注射维持12~72 h。比较两组治疗预后、不良反应发生情况及治疗前后血液流变学指标、凝血功能指标、美国国立卫生研究院卒中量表(NIHSS)评分、日常生活能力量表(ADL)评分的差异。结果:治疗2周后,观察组治疗总有效率为93.33%(28/30),高于对照组的73.33%(22/30,P <0.05)。治疗后,观察组红细胞沉降率(ESR)、红细胞聚集指数(EAI)检测结果均低于对照组(P <0.05);活化部分凝血活酶时间(APTT)检测结果高于对照组,D-二聚体(D-D)、纤维蛋白原(FIB)检测结果均低于对照组(P <0.05)。治疗后,观察组NIHSS评分低于对照组,ADL评分高于对照组(P <0.05)。观察组不良反应总发生率为13.33%(4/30),与对照组的10.00%(3/30)差异无统计学意义(P> 0.05)。结论:脑梗死急性期应用阿司匹林联合依替巴肽能够提升治疗预后,改善患者的神经功能和日常生活能力,值得临床推荐。
Objective: To investigate the effect of aspirin combined with etipatide on the treatment prognosis of acute stage of cerebral infarction. Methods: Sixty patients with acute cerebral infarction admitted to our hospital from March 2021to March 2022 were collected and the random number table method was used to divide the patients into a control group and an observation group with 30 cases in each group. The control group took aspirin 100 mg/time, once a day, for two consecutive weeks, and the observation group added the first dose of etibatide 135 μg/kg, intravenous injection on this basis, then 0.75 μg·kg^(-1)·min^(-1) micro pump injection for 12~72 hours. The prognosis, adverse reactions, hemorheology indexes, coagulation function indexes, national institutes of health stroke scale(NIHSS) scores and activity of daily living scale(ADL) scores of the two groups were compared before and after treatment. Results: After 2 weeks of treatment, the total effective rate in the observation group was 93.33%(28/30), which was higher than that of the control group 73.33%(22/30, P<0.05). After treatment, the results of erythrocyte sedimentation rate(ESR) and erythrocyte aggregation index(EAI) in the observation group were lower than those in the control group(P<0.05);the results of activated partial thromboplastin time(APTT) in the observation group were higher than those in the control group, while the results of D-dimer(D-D) and fibrinogen(FIB) were lower than those in the control group(P<0.05). After treatment, the NIHSS score in the observation group was lower than that in the control group, and the ADL score was higher than that in the control group(P<0.05). The total incidence of adverse reactions in the observation group was 13.33%(4/30), and there was no significant difference compared with 10.00%(3/30) in the control group(P>0.05). Conclusion:Aspirin combined with etibatide can improve the treatment prognosis of acute stage of cerebral infarction, neurological function and daily living ability of patients, which is
作者
钟岳飞
ZHONG Yuefei(Department of Neurology of People’s Hospital of Guangxin District,Shangrao City,Jiangxi Province 334100,China)
出处
《上海医药》
CAS
2023年第4期30-33,共4页
Shanghai Medical & Pharmaceutical Journal
关键词
脑梗死
阿司匹林
依替巴肽
预后
神经功能
cerebral infarction
aspirin
etibatide
prognosis
neurological function
